Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.63 |
| ▸ | MAOB | P27338 | 10/20 | 0.63 |
| ▸ | HTR2B | P41595 | 6/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.63 |
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | KDM1A | O60341 | 5/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16761697 | 1.00 | HTR2C (0.63) | HTR2CMAOBHTR2BHTR2AMAOA | |
| SCHEMBL9043644 | 1.00 | HTR2C (0.63) | HTR2CMAOBHTR2BHTR2AMAOA | |
| SCHEMBL1834561 | 1.00 | HTR2C (0.63) | HTR2CMAOBHTR2BHTR2AMAOA | |
| SCHEMBL21480339 | 0.88 | KDM1A (0.55) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL20208695 | 0.88 | KDM1A (0.55) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL25262357 | 0.83 | HTR2C (0.59) | HTR2CMAOBHTR2BHTR2AMAOA | |
| SCHEMBL17080568 | 0.78 | HTR2C (0.41) | HTR2CMAOBHTR2BHTR2ASLC6A2 | |
| SCHEMBL19262111 | 0.78 | HTR2C (0.63) | HTR2CHTR2BHTR2ASLC6A2SLC6A3 | |
| SCHEMBL16585035 | 0.78 | HTR2C (0.66) | HTR2CHTR2BHTR2AKDM1ASLC6A2 | |
| SCHEMBL2826042 | 0.78 | HTR2C (0.66) | HTR2CMAOBHTR2BHTR2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20240182462-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11926622-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023069720-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-114980887-A | Fluoroalkyl-oxadiazoles and their use | 特纳亚治疗股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021127643-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-1029230-C | Hydroxamic acid and N-hydroxyurea derivatives and their use | PFIZER (US) | 1995-07-05 | — | — | CN | disclosed |
| WO-1995013279-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1995-05-18 | — | — | WO | disclosed |
| EP-0559743-B1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0559743-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE. | PFIZER HOSPITAL PROD (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009566-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| CN-1061775-A | New hydroxamic acid and N-hydroxyl urea derivant and uses thereof | PFIZER (US) | 1992-06-10 | — | — | CN | disclosed |
| US-5089639-A | N-CYCLOALKYLALKYLAMINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT AND THEIR SYNTHESIS INTERMEDIATES | JOUVEINAL S.A. (FR) | 1992-02-18 | — | — | US | disclosed |
| EP-0446097-A1 | Substituted etylamines, process for their preparation, their use as therapeutic agents and intermediates for their synthesis | JOUVEINAL S.A. (FR) | 1991-09-11 | — | — | EP | disclosed |
| US-5034419-A | Psychological disorders or gastrointestinal disorders | L'OREAL (FR) | 1991-07-23 | — | — | US | disclosed |
| US-5017723-A | Psychotropic Agents | JOUVEINAL S.A. (FR) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11926622-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | HTR2C 3522/4885MAOB 760/4885HTR2B 3087/4885 |
| US-20240182462-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HTR2C 3522/4885MAOB 760/4885HTR2B 3087/4885 |
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | HTR2C 3470/4885MAOB 3674/4885HTR2B 4303/4885 |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | HTR2C 3522/4885MAOB 760/4885HTR2B 3087/4885 |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | HTR2C 3522/4885MAOB 760/4885HTR2B 3087/4885 |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HTR2C 3066/4885MAOB 632/4885HTR2B 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.